In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143).
The researchers suggest future prospective studies of acute relapse and disease-modifying treatment courses during and after pregnancy to ultimately improve treatment regimens for patients with NMOSD.
A proper MS diagnosis can only be made after obtaining imaging from the entire brain and understanding the clinical context.
In women with NMOSD, 42.9% of pregnancies ended in miscarriage compared with 12-24% in the general population.
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
- Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure